Jose A. Cocco-Maldonado

Buenos Aires, C, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.

Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.

Journal: Advances in therapy

Published: May 05, 2025

Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.

Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.

Journal: Rheumatology and therapy

Published: April 18, 2025

Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations.

Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations.

Journal: The Journal of rheumatology

Published: March 05, 2025

Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations.

Clinical Expression of Radiographic Axial Spondyloarthritis and Its Association With HLA-B27 in European and Ibero-American Populations.

Journal: The Journal of rheumatology

Published: January 03, 2025

Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA study.

Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA study.

Journal: RMD open

Published: July 13, 2024

Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study.

Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study.

Journal: Rheumatology (Oxford, England)

Published: May 14, 2024

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.

Journal: Rheumatology (Oxford, England)

Published: May 21, 2021

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study.

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study.

Journal: RMD open

Published: May 05, 2021

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study.

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study.

Journal: RMD open

Published: September 14, 2020

Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America.

Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America.

Journal: Clinical rheumatology

Published: July 12, 2019

Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America.

Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America.

Journal: Clinical rheumatology

Published: July 12, 2019

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.

Journal: Rheumatology (Oxford, England)

Published: March 11, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026